Señales en vivo de VRCI.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 04:28):
Our systems believe the stock currently is overvalued by -0.07% compare to its pairs and should correct downwards.

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients...

Stats
Volumen de hoy	349 121
Volumen promedio	350 876
Capitalización de mercado	15.89M
EPS	£-0.0155 ( Q2 \| 2023-06-30 )
Próxima fecha de ganancias	( £0 ) 2024-09-24
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.640 (Sector) 464.83 (Industry) 0
ATR14	£0.294 (4.49%)

ABDX.L -0.10%

GENI.L -3.59%

VRCI.L 4.82%

Correlación (AI algo v.1.1b): Overvalued: -0.07% £6.56 paired level. (El Algoritmo Rastrea Los Cambios De Las Acciones Más Correlacionadas En Tiempo Real Y Proporciona Una Actualización Instantánea)

Verici Dx plc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Verici Dx plc Finanzas

Annual	2023
Ingresos:	£1.01M
Beneficio Bruto:	£1.01M (100.00 %)
EPS:	£-0.0513

FY	2023
Ingresos:	£1.01M
Beneficio Bruto:	£1.01M (100.00 %)
EPS:	£-0.0513

FY	2022
Ingresos:	£0
Beneficio Bruto:	£0 (0.00 %)
EPS:	£-0.0690

FY	2021
Ingresos:	£0.00
Beneficio Bruto:	£0.00 (0.00 %)
EPS:	£-4.89

Financial Reports:

No articles found.

Verici Dx plc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Verici Dx plc

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.